Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma.
Using microarrays, we have screened for genes reactivated by drugs that modify epigenetic mechanisms in pancreatic cancer cells. One of the genes identified was tissue factor pathway inhibitor 2 (TFPI-2), which encodes for a broad-spectrum serine proteinase inhibitor that negatively regulates the extracellular matrix degradation, an essential step in tumor invasion and metastasis. We therefore investigated the expression and methylation patterns of the TFPI-2 gene in pancreatic adenocarcinoma, and determined its role in tumor growth and invasion. In contrast to its abundant expression in normal pancreas, TFPI-2 mRNA was undetectable in a high fraction of pancreatic cancer cell lines and in primary pancreatic ductal neoplasms (IPMNs). Loss of TFPI-2 expression was associated with aberrant hypermethylation of its promoter CpG island. Treatment with the phorbol ester (PMA), known to stimulate the TFPI-2 promoter activity, augmented the TFPI-2 expression in cell lines with unmethylated or partially methylated TFPI-2, but failed to induce the expression in cell lines that harbored fully methylated TFPI-2. Aberrant methylation of TFPI-2 was also detected in 73% (102/140) of pancreatic cancer xenografts and primary pancreatic adenocarcinomas, was more likely in older patients with pancreatic cancer, and significantly correlated with progression of IPMNs (P=0.0002). Restored expression of the TFPI-2 gene in nonexpressing pancreatic cancer cells resulted in marked suppression in their proliferation, migration, and invasive potential in vitro. We thus conclude that epigenetic inactivation of TFPI-2 is a common mechanism that contributes to the aggressive phenotype of pancreatic ductal adenocarcinoma.
Sato
Norihiro
N
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA.
Parker
Antony R
AR
Fukushima
Noriyoshi
N
Miyagi
Yohei
Y
Iacobuzio-Donahue
Christine A
CA
Eshleman
James R
JR
Goggins
Michael
M
D000230:Adenocarcinoma / Q000235:genetics* / Q000601:surgery; D000964:Antimetabolites, Antineoplastic / Q000633:toxicity; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000633:toxicity*; D001483:Base Sequence; D021441:Carcinoma, Pancreatic Ductal / Q000235:genetics* / Q000601:surgery; D045744:Cell Line, Tumor; D017931:DNA Primers; D000077209:Decitabine; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D006877:Hydroxamic Acids / Q000633:toxicity; D019656:Loss of Heterozygosity; D020411:Oligonucleotide Array Sequence Analysis; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000601:surgery; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014183:Transplantation, Heterologous
D000964:Antimetabolites, Antineoplastic; D017931:DNA Primers; D006023:Glycoproteins; D006877:Hydroxamic Acids; C021240:tissue-factor-pathway inhibitor 2; C012589:trichostatin A; D000077209:Decitabine; D001374:Azacitidine